Vaccinex(VCNX)
ROCHESTER, NY
BiotechnologyFocus: Human therapeutic monoclonal antibodies and other targeted biological therapies
Vaccinex is a life sciences company focused on Human therapeutic monoclonal antibodies and other targeted biological therapies.
Vaccines
Funding Stage
PUBLIC
Open Jobs
0
Pipeline & Clinical Trials
Phase 1
Clinical Trials (1)
NCT03690986VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer
Phase 1Anti-SEMA4D Monoclonal Antibody VX15/2503
Metastatic MelanomaVX15/2503
Solid TumorsClinical Trials (1)
NCT01313065Evaluation of Safety, Tolerability, PK & PD of Intravenous VX15/2503 in Patients With Advanced Solid Tumors
Phase 1Phase 1
Dendritic Cell
HER2-positive Breast CancerClinical Trials (1)
NCT05378464Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer
Phase 1VX15/2503
Multiple SclerosisClinical Trials (1)
NCT01764737Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS
Phase 1Anti-SEMA4D Monoclonal Antibody VX15/2503
Colon Carcinoma Metastatic in the LiverClinical Trials (1)
NCT03373188VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer
Phase 1Pepinemab
Alzheimer DiseaseClinical Trials (1)
NCT04381468SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD)
Phase 1/2pepinemab + pembrolizumab
Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)Avelumab and Pepinemab
Metastatic Pancreatic AdenocarcinomaClinical Trials (1)
NCT05102721Trial of Immunotherapy With Avelumab and Pepinemab As Second Line For Patients With Metastatic Pancreatic Adenocarcinoma
Phase 1/2VX15/2503 + avelumab
Carcinoma, Non-Small-Cell LungVX15/2503
Huntington's DiseaseClinical Trials (1)
NCT02481674A Study in Subjects With Late Prodromal & Early Manifest HD to Assess the Safety, Tolerability, pk, and Efficacy of Pepi
Phase 2Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Portfolio: 8 clinical trials
SEC Filings: 2 available
Financials (FY2024)
Revenue
$570K107%
R&D Spend
$17M(2908%)19%
Net Income
-$20MCash
$2M